TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
1.080
+0.045 (4.35%)
At close: Mar 4, 2026, 4:00 PM EST
1.090
+0.010 (0.93%)
After-hours: Mar 4, 2026, 7:01 PM EST

TScan Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
10.332.8221.0513.5410.14
Revenue Growth (YoY)
266.65%-86.62%55.52%33.47%834.65%
Gross Profit
10.332.8221.0513.5410.14
Selling, General & Admin
63.9860.5726.3520.3513.83
Research & Development
228.3214.788.1559.8244.95
Total Operating Expenses
292.28275.27114.5180.1758.78
Operating Income
-135.81-134.82-93.46-66.64-48.64
Interest Income
8.8212.0781.590.02
Interest Expense
-2.77-3.65-3.76-1.18-
Other Non-Operating Income (Expense)
--1.09---
Total Non-Operating Income (Expense)
6.057.324.240.420.02
Pretax Income
-129.77-127.5-89.22-66.22-48.63
Net Income
-129.77-127.5-89.22-66.22-48.63
Net Income to Common
-129.77-127.5-89.22-66.22-48.63
Shares Outstanding (Basic)
130112662412
Shares Outstanding (Diluted)
130112662412
Shares Change (YoY)
15.88%70.72%172.78%106.20%1173.20%
EPS (Basic)
-1.00-1.14-1.36-2.75-4.17
EPS (Diluted)
-1.00-1.14-1.36-2.75-4.17
Free Cash Flow
-139.73-114.65-64.5-70.73-58.62
Free Cash Flow Per Share
-1.08-1.02-0.98-2.94-5.03
Gross Margin
100.00%100.00%100.00%100.00%100.00%
Operating Margin
-1315.38%-4787.68%-444.00%-492.32%-479.65%
Profit Margin
-1256.81%-4527.66%-423.86%-489.26%-479.49%
FCF Margin
-1353.28%-4071.27%-306.45%-522.56%-578.03%
EBITDA
-132.95-130.71-88.1-61.5-45.31
EBITDA Margin
-1287.62%-4641.80%-418.53%-454.37%-446.83%
EBIT
-135.81-134.82-93.46-66.64-48.64
EBIT Margin
-1315.38%-4787.68%-444.00%-492.32%-479.65%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q